Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wednesday broker round-up UPDATE

Wed, 16th Jan 2013 07:16

Anglo American: Goldman Sachs reduces target price from 1650p to 1500p and reiterates its sell recommendation.Antofagasta: Goldman Sachs ups target price from 1100p to 1120p and still recommends to sell.ARM Holdings: UBS increases target price from 750p to 900p, while downgrading to neutral.Ashtead Group: Credit Suisse raises target price from 400p to 545p retaining an outperform rating.Balfour Beatty: Credit Suisse shifts target price from 275p to 279p and keeps a neutral rating.Barclays: Nomura ups target price from 230p to 270p maintaining a reduce rating.Barratt Developments: Panmure Gordon shifts target price from 211p to 220p and retains a hold recommendation.Berendsen: Credit Suisse increases target price from 640p to 710p and maintains an outperform rating.BHP Billiton: JP Morgan takes target price from 2245p to 2300p and keeps a neutral rating. Goldman Sachs ups target price from 2400p to 2450p, while its buy recommendation remains unchanged.Brammer: Jefferies raises target price from 295p to 340p and downgrades from buy to hold.BT Group: Deutsche Bank increases target price from 235p to 269p, while retaining a hold rating.Burberry Group: UBS moves target price from 1170p to 1350p and reiterates a neutral rating. Credit Suisse ups target price from 1430p to 1550p, while staying with its outperform rating. Berenberg takes price target from 1400p to 1600p keeping a buy recommendation.Capital Shopping Centres Group: JP Morgan increases target price from 380p to 400p and upgrades to neutral.Carillion: Credit Suisse ups target price from 316p to 349p and downgrades to neutral.Centrica: Barclays raises target price from 305p to 325p and keeps an underweight rating.Charlemagne Capital: JP Morgan shifts target price from 5p to 7p, while retaining an underweight rating.COLT Telecom Group: Deutsche Bank cuts target price from 155p to 145p, while its buy recommendation is reiterated.Communisis: Panmure Gordon downgrades from buy to hold with its target price still at 47p.Diageo: Nomura lowers target price from 2070p to 2040p, while the buy rating is kept. Societe Generale reduces target price from 2050p to 1900p and downgrades to hold.Eurasian Natural Resources Corporation: JP Morgan ups target price from 275p to 300p, while the neutral rating is maintained.Fenner: Investec shifts target price from 415p to 420p, while retaining a hold rating.French Connection: Seymour Pierce cuts target price from 25p to 20p still recommending to hold.Glaxo Smith Kline: Jefferies raises target price from 1450p to 1500p and reiterates a hold rating.Home Retail Group: Barclays shifts target price from 70p to 73p and retains an underweight rating.HSBC Holdings: Nomura increases target price from 660p to 730p staying with its buy recommendation.Intermediate Capital Group: Deutsche Bank ups target price from 298p to 322p and keeps a hold rating.ITV: JP Morgan moves target price from 109p to 120p and downgrades to neutral.Kazakhmys: Goldman Sachs cuts target price from 850p to 820p, while its neutral rating is reiterated.Liontrust Asset Management: JP Morgan ups target price from 112p to 134p, while keeping an underweight rating.Lonmin: After Lonmin has not been rated, Investec recommends to hold with its target price at 353p.Lloyds Banking Group: Nomura shifts target price from 37p to 42p and maintains a reduce rating.MITIE Group: Credit Suisse reduces target price from 290p to 250p and keeps an underperform rating.N Brown: Seymour Pierce moves target price from 280p to 360p reiterating its hold recommendation.Provident Financial: JP Morgan ups target price from 1626p to 1646p, while maintaining an overweight rating.Rio Tinto: UBS reduces target price from 4340p to 4320p keeping its buy recommendation. JP Morgan raises target price from 4200p to 4400p and reiterates an overweight rating. Goldman Sachs increases target price from 3400p to 3800p, while its neutral rating remains unchanged. Deutsche Bank lowers target price from 4520p to 4450p and maintains a buy recommendation. Morgan Stanley downgrades to equalweight. Rolls-Royce Group: Credit Suisse takes price target from 850p to 900p and retains a neutral rating.Royal Bank of Scotland: Nomura raises target price from 270p to 300p and stays with a reduce rating.RPS Group: Investec moves target price from 270p to 275p keeping a buy recommendation.SAB Miller: Nomura shifts target price from 2800p to 2840p maintaining a neutral rating.Signet Jewelers: UBS ups target price from 3700p to 4050p, while its buy recommendation remains unchanged.Standart Chartered: Nomura moves target price from 1600p to 1800p reiterating a buy rating.Tarsus Group: Investec takes price target from 210p to 215p, while its buy rating in unchanged.Thorntons: Investec increases target price from 30p to 45p and stays with a hold recommendation.Virgin Media: Deutsche Bank raises target price from 2325p to 3154p, while its buy recommendation is maintained.Vodafone: Deutsche Bank cuts target price from 225p to 175p and downgrades to hold.Wetherspoon JD: Investec lowers target price from 570p to 550p and retains its buy recommendation.
More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.